Faculty profile

Robert Kerbel

Back to faculty

Professor Emeritus/EmeritaDepartment of Medical BiophysicsUniversity of Toronto

Robert Kerbel

Professor Emeritus/Emerita

Department of Medical Biophysics

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Canada Research Chair in Tumor Biology - Tier 1

ORCID

Supervision signals

Emeritus professors are retired and rarely take new students.
No publications since 2018.
Principal investigator on 3 research grants (3 CIHR), most recently in 2019.
Supervised 4 trainees who won CIHR awards, most recently in 2012.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Education

Profiles and links

University Profile Search on Google Scholar iDORCID

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Immune Checkpoint Inhibitors Metastatic Therapy Metronomic Chemotherapy Acquired Resistance Combination Therapy Innate Resistance Maintenance Therapy New Preclinical Models

Latest papers

Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.
PloS one · 2018
Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials.
Clinical lung cancer · 2017
Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?
European journal of cancer (Oxford, England : 1990) · 2017 · senior author

All 11 publications

Latest funding

Low Dose Metronomic Chemotherapy as a Combination Strategy to Combat Innate or Acquired Resistance to Immune Checkpoint Therapy
CIHR · 2019 · Nominated PI
$581,400
Ultrasound-Mediated Drug Delivery to the Spinal Cord
CIHR · 2018 · Co-investigator
$673,200
Enhancing immunotherapy with ultrasound stimulated bubbles
CIHR · 2017 · Co-investigator
$776,475

All 11 grants and awards

11 publications.

Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.

Fricke IB, De Souza R, Costa Ayub L, Francia G, Kerbel R, Jaffray DA, Zheng J

PloS one2018

DOI: 10.1371/journal.pone.0196892 PMID: 29723251

Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials.

Raphael J, Chan K, Karim S, Kerbel R, Lam H, Santos KD, Saluja R, Verma S

Clinical lung cancer2017

DOI: 10.1016/j.cllc.2017.01.004 PMID: 28188101

Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?

Rana P, Pritchard KI, Kerbel R

European journal of cancer (Oxford, England : 1990)2017Senior author

DOI: 10.1016/j.ejca.2016.11.002 PMID: 27916568

Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.

Pantziarka P, Hutchinson L, André N, Benzekry S, Bertolini F, Bhattacharjee A, Chiplunkar S, Duda DG, Gota V, Gupta S, Joshi A, Kannan S, Kerbel R, Kieran M, Palazzo A, Parikh A, Pasquier E, Patil V, Prabhash K, Shaked Y, Sholler GS, Sterba J, Waxman DJ, Banavali S

Ecancermedicalscience2016

DOI: 10.3332/ecancer.2016.689 PMID: 27994645

Antiangiogenic therapy in oncology: current status and future directions.

Jayson GC, Kerbel R, Ellis LM, Harris AL

Lancet (London, England)2016

DOI: 10.1016/s0140-6736(15)01088-0 PMID: 26853587

Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival.

Alkins R, Burgess A, Kerbel R, Wels WS, Hynynen K

Neuro-oncology2016

DOI: 10.1093/neuonc/nov318 PMID: 26819443

Lessons from the first ecancer symposium on angiogenesis in gastric cancer.

Nailor A, Dejana E, Reynolds AR, Punwani S, Curigliano G, Bertolini F, Shah M, Danesi R, Kerbel R, McVie G

Ecancermedicalscience2015

DOI: 10.3332/ecancer.2015.553 PMID: 26284117

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.

Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, Cavallaro U, Cinieri S, Colleoni M, Curigliano G, Di Desidero T, Eniu A, Fazio N, Kerbel R, Hutchinson L, Ledzewicz U, Munzone E, Pasquier E, Graciela Scharovsky O, Shaked Y, Stěrba J, Villalba M, Bertolini F

Ecancermedicalscience2014

DOI: 10.3332/ecancer.2014.463 PMID: 25228919

Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.

Buckstein R, Kerbel R, Cheung M, Shaked Y, Chodirker L, Lee CR, Lenis M, Davidson C, Cussen MA, Reis M, Chesney A, Zhang L, Mamedov A, Wells RA

Leukemia research2014

DOI: 10.1016/j.leukres.2014.03.022 PMID: 24819395

Focused ultrasound delivers targeted immune cells to metastatic brain tumors.

Alkins R, Burgess A, Ganguly M, Francia G, Kerbel R, Wels WS, Hynynen K

Cancer research2013

DOI: 10.1158/0008-5472.can-12-2609 PMID: 23302230

Low Dose Metronomic Chemotherapy as a Combination Strategy to Combat Innate or Acquired Resistance to Immune Checkpoint Therapy

Nominated PICIHR2019Project Grant

Principal investigators: Kerbel, Robert S

Keywords: Acquired Resistance; Combination Therapy; Immune Checkpoint Inhibitors; Innate Resistance; Maintenance Therapy; Metastatic Therapy; Metronomic Chemotherapy; New Preclinical Models; Pd-L1

$581,400

Ultrasound-Mediated Drug Delivery to the Spinal Cord

Co-investigatorCIHR2018Project Grant

Principal investigators: O'Reilly, Meaghan

Keywords: Blood-Spinal Cord Barrier; Drug Delivery; Focused Utrasound,; Image-Guided Therapy; Spinal Cord

$673,200

Enhancing immunotherapy with ultrasound stimulated bubbles

Co-investigatorCIHR2017Project Grant

Principal investigators: Goertz, David E

Keywords: Cancer; Immunotherapy; Microbubbles; Therapeutic Ultrasound

$776,475

Preclinical approach to improve testing of immuno-oncology combination therapies for early or late stage metastatic disease

Nominated PICIHR2016Project Grant

Principal investigators: Kerbel, Robert S

Keywords: Adjuvant Therapy; Animal Models; Chemotherapy - General; Experimental Therapeutics; Imaging; Immune Checkpoint Inhibitors; Immuno-Oncology; Metastatic Therapy; Metronomic Chemotherapy; Tumor Angiogenesis

$607,780

Development of the next generation ultrasound therapy

Co-investigatorCIHR2016Foundation Grant

Principal investigators: Hynynen, Kullervo H

Keywords: Bioeffects; Image Guided Interventions; Therapy; Ultrasound

$2,273,295

Development of next generation ultrasound imaging

Co-investigatorCIHR2015Foundation Grant

Principal investigators: Foster, F. Stuart; Burns, Peter N

Keywords: Blood Flow Imaging; Cancer Models; Contrast Agents; Gas Vesicles; Mouse Imaging; Nanotechnology; Nonlinear Ultrasound Imaging; Potentiated Therapeutics; Ultrasound Imaging And Doppler; Ultrasound Transducers

$3,676,386

Does Metronomic Chemotherapy Preferentially Target Ovarian Cancer Stem Cells?

SupervisorCIHR2012CIHR Fellowship

Principal investigators: Pham, Elizabeth

Keywords: Antiangiogenic Therapy; Cancer Stem Cells; Flow Cytometry; Metronomic Chemotherapy; Ovarian Cancer; Preclinical In Vivo Tumour Models; Therapy Response; Tumour Imaging

$135,000

Impact of Chemotherapy-Induced Activation of Platelets on Therapeutic Efficacy Outcomes

SupervisorCIHR2011CIHR Fellowship

Principal investigators: Milsom, Chloe C

Keywords: Cancer; Chemokines/Cytokines; Chemotherapy; Host-Response; Platelets; Stromal Cell-Derived Factor-1 (Sdf-1); Targeted Therapy; Tumour Angiogenesis

$90,000

Translational studies of acquired resistance to antiangiogenic therapies undertaken in new preclinical models of locally advanced or metastatic cancer

Nominated PICIHR2011Operating Grant

Principal investigators: Kerbel, Robert S

Keywords: Antiangiogenic Therapy; Biomarkers; Chemotherapy; Experimental Therapeutics; Liver Cancer; Metastasis; Ovarian Cancer; Tumor Models; Tyrosine Kinase Inhibitors; Vegf

$781,655

Angiopoietin-1 mimetics: new therapeutic agents for cancer treatment.

SupervisorCIHR2010Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Wu, Florence T

Keywords: Angiopoietin-1 Mimetics; Anti-Metastatic Therapy; In Vivo Bioluminescent Imaging Of Tumor Progression; Inflammation; Mouse Models Of Cancer And Metastasis; Tie2 Receptor; Tumor Angiogenesis; Vascular Stabilization; Vasculature-Targeted Cancer Treatment

$70,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2019

Subject: Prospective PhD student: Immune Checkpoint Inhibitors Dear Professor Kerbel, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice." (2018), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Low Dose Metronomic Chemotherapy as a Combination Strategy to Combat Innate or Acquired Resistance to Immune Checkpoint Therapy" (2019), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Robert Kerbel

Research

Latest papers

Latest funding

Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.

Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials.

Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?

Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.

Antiangiogenic therapy in oncology: current status and future directions.

Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival.

Lessons from the first ecancer symposium on angiogenesis in gastric cancer.

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.

Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.

Focused ultrasound delivers targeted immune cells to metastatic brain tumors.

Low Dose Metronomic Chemotherapy as a Combination Strategy to Combat Innate or Acquired Resistance to Immune Checkpoint Therapy

Ultrasound-Mediated Drug Delivery to the Spinal Cord

Enhancing immunotherapy with ultrasound stimulated bubbles

Preclinical approach to improve testing of immuno-oncology combination therapies for early or late stage metastatic disease

Development of the next generation ultrasound therapy

Development of next generation ultrasound imaging

Does Metronomic Chemotherapy Preferentially Target Ovarian Cancer Stem Cells?

Impact of Chemotherapy-Induced Activation of Platelets on Therapeutic Efficacy Outcomes

Translational studies of acquired resistance to antiangiogenic therapies undertaken in new preclinical models of locally advanced or metastatic cancer

Angiopoietin-1 mimetics: new therapeutic agents for cancer treatment.

Frequent collaborators

Kullervo Hynynen

Sunil Verma

Lisa Chodirker

Urban Emmenegger

Kelvin Chan

Jinzi Zheng